A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung Cancer. Issue 4 (April 2019)
- Record Type:
- Journal Article
- Title:
- A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung Cancer. Issue 4 (April 2019)
- Main Title:
- A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung Cancer
- Authors:
- Taylor, Clive R.
Jadhav, Anagha P.
Gholap, Abhi
Kamble, Gurunath
Huang, Jiaoti
Gown, Allen
Doshi, Isha
Rimm, David L. - Abstract:
- Abstract : Assessment of programmed death-ligand 1 ( PD-L1 ) expression is a critical part of patient management for immunotherapy. However, studies have shown that pathologist-based analysis lacks reproducibility, especially for immune cell expression. The purpose of this study was to validate reproducibility of the automated machine-based Optra image analysis for PD-L1 immunohistochemistry for both tumor cells (TCs) and immune cells. We compared conventional pathologists' scores for both tumor and immune cell positivity separately using 22c3 antibody on the Dako Link 48 platform for PD-L1 expression in non–small cell lung carcinoma. We assessed interpretation first by pathologists and second by PD-L1 image analysis scores. Lin's concordance correlation coefficients (LCCs) for each pathologist were measured to assess variability between pathologists and between pathologists and Optra automated quantitative scores in scoring both tumor and immune cells. Lin's LCCs to evaluate the correlation between pathologists for TC was 0.75 [95% confidence interval (CI), 0.64-0.81] and 0.40 (95% CI, 0.40-0.62) for immune cell scoring. Pathologists were highly concordant for tumor scoring, but not for immune cell scoring, which is similar to previously reported studies where agreement is higher in TCs than immune cells. The LCCs between conventional pathologists' read and the machine score were 0.80 (95% CI, 0.74-0.85) for TCs and 0.70 (95% CI, 0.60-0.76) for immune cell population. ThisAbstract : Assessment of programmed death-ligand 1 ( PD-L1 ) expression is a critical part of patient management for immunotherapy. However, studies have shown that pathologist-based analysis lacks reproducibility, especially for immune cell expression. The purpose of this study was to validate reproducibility of the automated machine-based Optra image analysis for PD-L1 immunohistochemistry for both tumor cells (TCs) and immune cells. We compared conventional pathologists' scores for both tumor and immune cell positivity separately using 22c3 antibody on the Dako Link 48 platform for PD-L1 expression in non–small cell lung carcinoma. We assessed interpretation first by pathologists and second by PD-L1 image analysis scores. Lin's concordance correlation coefficients (LCCs) for each pathologist were measured to assess variability between pathologists and between pathologists and Optra automated quantitative scores in scoring both tumor and immune cells. Lin's LCCs to evaluate the correlation between pathologists for TC was 0.75 [95% confidence interval (CI), 0.64-0.81] and 0.40 (95% CI, 0.40-0.62) for immune cell scoring. Pathologists were highly concordant for tumor scoring, but not for immune cell scoring, which is similar to previously reported studies where agreement is higher in TCs than immune cells. The LCCs between conventional pathologists' read and the machine score were 0.80 (95% CI, 0.74-0.85) for TCs and 0.70 (95% CI, 0.60-0.76) for immune cell population. This is considered excellent agreement for TCs and good concordance for immune cells. The automated scoring methods showed concordance with the pathologists' average scores that were comparable to interpathologist scores. This suggests promise for Optra automated assessment of PD-L1 in non–small cell lung cancer. … (more)
- Is Part Of:
- Applied immunohistochemistry & molecular morphology. Volume 27:Issue 4(2019)
- Journal:
- Applied immunohistochemistry & molecular morphology
- Issue:
- Volume 27:Issue 4(2019)
- Issue Display:
- Volume 27, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 27
- Issue:
- 4
- Issue Sort Value:
- 2019-0027-0004-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-04
- Subjects:
- immunotherapy -- PD-L1 immunohistochemistry -- non–small cell lung cancer -- image analysis
Diagnostic immunohistochemistry -- Periodicals
Immunohistochemistry -- Periodicals
Cells -- Morphology -- Periodicals
Molecular diagnosis -- Periodicals
616.079 - Journal URLs:
- http://journals.lww.com/appliedimmunohist/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/PAI.0000000000000737 ↗
- Languages:
- English
- ISSNs:
- 1541-2016
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1573.140000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11954.xml